Antimicrobial Resistance Linked to $3.5 Trillion Losses in 2021
New research reveals antimicrobial resistance caused significant global economic losses, impacting GDP and healthcare systems.
Antimicrobial resistance resulted in $3.5 trillion in global economic losses in 2021.
Bloodstream infections were the leading cause, accounting for $355 billion in losses.
South Asia experienced the highest absolute losses, while Western sub-Saharan Africa faced the largest proportional impact.
A recent study presented at IDWeek 2026 has revealed that antimicrobial resistance (AMR) was responsible for a staggering $3.5 trillion in global economic losses in 2021. This figure represents approximately 2.25% of the world's gross domestic product (GDP), with $835 billion directly linked to AMR. The findings underscore the urgent need for effective strategies to combat drug-resistant infections worldwide.
The research utilized data from the Global Burden of Disease 2021 MICROBE tool, examining disability-adjusted life-years (DALYs) alongside GDP and population statistics. The analysis encompassed 21 regions, 12 infectious syndromes, and 22 bacterial pathogens, revealing that AMR accounted for 42.6 million attributable DALYs and was associated with a total of 177.7 million DALYs globally. This distinction highlights the additional burden of infections caused specifically by resistant organisms.
Among the various infection types, bloodstream infections emerged as the most significant contributor to economic losses, totaling $355 billion, which represents 42.5% of the overall losses attributed to AMR. Lower respiratory infections, including pneumonia, added another $261 billion, accounting for 31.3%. Together, these two categories constituted nearly three-quarters of the economic burden directly linked to antimicrobial resistance.
Six bacterial pathogens were identified as responsible for approximately 82% of the attributable losses, with Klebsiella pneumoniae leading at $130 billion, followed closely by Streptococcus pneumoniae and Acinetobacter baumannii. Notably, gram-negative bacteria were responsible for over 60% of these losses, emphasizing their critical role in the global challenge of drug-resistant infections.
Geographically, the analysis indicated that South Asia faced the highest absolute economic losses at $101 billion, followed by East Asia at $82 billion and high-income North America at $70 billion. In terms of proportional impact, Western sub-Saharan Africa experienced the greatest burden, with losses equivalent to 1.42% of its regional GDP. These findings highlight the necessity for enhanced antimicrobial stewardship, improved diagnostic methods, vaccination efforts, and equitable access to antibiotics to mitigate the economic and health impacts of AMR.
